Johnson & Johnson (JNJ)

Johnson & Johnson's stock (JNJ) has experienced a rally, adding 30% from late June to an all-time high logged in October 2025. As of October 27, 2025, the stock was up 7.76% over the past 30 days and 16.33% for the past 12 months. JNJ's Q3 2025 earnings report topped estimates and hiked guidance. The Innovative Medicine unit showed a 3.4% organic sales rise in the first nine months of 2025, despite the loss of exclusivity for Stelara and the negative impact of the Part D redesign. However, the company has also faced challenges, including a 17% jump in new lawsuits claiming its baby powder causes cancer after a global settlement attempt was rejected in bankruptcy court.

The demand for Johnson & Johnson's products and services is generally less susceptible to extreme seasonality compared to consumer goods. Healthcare demand tends to be more consistent, driven by ongoing medical needs, disease prevalence, and healthcare system operations. The company's diversified business model helps it to withstand economic cycles more effectively.

Johnson & Johnson is a healthcare company focused on researching, developing, manufacturing, and selling innovative medicines and medical technologies. The company operates through two segments: Innovative Medicine, providing pharmaceutical products for various therapy areas, and MedTech, offering medical devices for cardiovascular, orthopedic, neurovascular care, general surgery, and vision care fields. In 2023, Johnson & Johnson spun off its consumer health business, Kenvue, to focus on innovative pharmaceuticals and medical devices.

Johnson & Johnson has a significant global presence, operating manufacturing units in the US, Europe, Asia-Pacific, Africa, Western Hemisphere (excluding the US), and Latin America. The company has over 275 subsidiaries and operations in more than 60 countries worldwide. Over half of its revenue is generated from the United States, and its international operations provide growth potential in emerging markets as healthcare infrastructure improves. Johnson & Johnson Innovation, LLC (JJI), a subsidiary, has regional innovation teams operating out of four Innovation Centers and offers incubation and acceleration through 11 JLABS locations globally and virtually.

Johnson & Johnson has consistently maintained a strong brand reputation. The company was named to Fortune's World's Most Admired Companies list for the 22nd consecutive year in 2024. In 2023, Johnson & Johnson was recognized as the pharma industry's most valuable company and strongest brand for the fifth consecutive year. However, the company has faced significant legal and ethical challenges, including lawsuits related to its talc powder and hip implant failures.

Institutional investors hold a substantial portion of Johnson & Johnson's outstanding shares, accounting for 73.57% as of December 2024. The ten largest shareholders include The Vanguard Group (9.67%), BlackRock (8.36%), and State Street Corporation (5.58%). Individual insiders hold a smaller percentage, approximately 0.0461% of shares.